Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
61.04
-0.72 (-1.17%)
Apr 25, 2025, 12:02 PM EDT - Market open
Sarepta Therapeutics Revenue
In the year 2024, Sarepta Therapeutics had annual revenue of $1.90B with 52.97% growth. Sarepta Therapeutics had revenue of $658.41M in the quarter ending December 31, 2024, with 65.94% growth.
Revenue (ttm)
$1.90B
Revenue Growth
+52.97%
P/S Ratio
3.09
Revenue / Employee
$1,386,282
Employees
1,372
Market Cap
5.92B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.90B | 658.64M | 52.97% |
| Dec 31, 2023 | 1.24B | 310.32M | 33.26% |
| Dec 31, 2022 | 933.01M | 231.13M | 32.93% |
| Dec 31, 2021 | 701.89M | 161.79M | 29.96% |
| Dec 31, 2020 | 540.10M | 159.27M | 41.82% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
SRPT News
- 1 day ago - SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - PRNewsWire
- 3 days ago - Sarepta Therapeutics to Announce First Quarter 2025 Financial Results - Business Wire
- 10 days ago - Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs - Business Wire
- 21 days ago - Sarepta halts three studies testing gene therapy for muscle disorder - Reuters
- 21 days ago - Sarepta Therapeutics Provides Update on ELEVIDYS - Business Wire
- 21 days ago - Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death - Benzinga
- 22 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Shareholders to Connect - Accesswire
- 23 days ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sarepta Therapeutics, Inc. (SRPT) And Encourages Shareholders to Reach Out - Accesswire